Why the study?
Right ventricular dysfunction is an independent prognostic factor in chronic heart failure, but poor evidence exists regarding the effect of guideline-directed medical therapy on it.
Does dapagliflozin improve right ventricular function, pulmonary pressure, and coupling in patients with chronic heart failure?
Population
142 patients with chronic heart failure
Comparison
Standard HF therapy plus dapagliflozin vs standard therapy without dapagliflozin
Design
Prospective observational registry with propensity score analysis
Follow-up
6 months
Key result
Dapagliflozin was associated with improved right ventricular global longitudinal strain compared with standard therapy in patients with chronic heart failure (adjusted mean difference -1.54%, P<0.001).
Authors
Loading...
May indicate RV benefit from dapagliflozin in chronic HF; hypothesis-generating and should not change practice pending RCTs.
Observational (n=142)
Does dapagliflozin improve right ventricular function, pulmonary pressure, and coupling in patients with chronic heart failure?
Mean Difference: -1.54
p-value: p=<0.001
In a real-world chronic heart failure cohort, the addition of dapagliflozin to standard therapy was associated with significant improvements in right ventricular function, pulmonary pressures, and RV-PA coupling at 6 months.
Palazzuoli et al. (2026) conducted an observational in Chronic heart failure (n=142). Dapagliflozin vs. Standard heart failure therapy without dapagliflozin was evaluated on Right ventricular global longitudinal strain (RVGLS) change from baseline to 6 months (adjusted mean difference -1.54%, p=<0.001). Dapagliflozin was associated with improved right ventricular global longitudinal strain compared with standard therapy in patients with chronic heart failure (adjusted mean difference -1.54%, P<0.001).